Xenetic reports first patient dosed in DNase-CAR T combination study for large B-cell lymphoma
XBIO•Xenetic Biosciences said the first patient was dosed in a 12-patient study combining systemic DNase with CAR T-cell therapy for large B-cell lymphoma.
1. Study begins
The study at Tel Aviv Sourasky University Medical Center is the technology’s first clinical evaluation alongside CAR T-cell therapy. Researchers will assess whether DNase improves treatment response by helping CAR T cells expand and persist, with outcomes including survival at 12 months evaluated during follow-up.
